Filip Prusinowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Filip Prusinowski has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Magdalena Stabrawa
Medical University of Łódź al. Kościuszki 4, 90-419 Łódź, Poland
6 shared publications - Ewelina Młynarska
Department of Nephrocardiology, Medical University of Lodz, 90-419 Lodz, Poland
3 shared publications - Ignacy Hatala
Medical University of Lodz, Al. Kościuszki 4, 90-419 Łódź, Poland
3 shared publications - Jacek Rysz
Department of Nephrology, Hypertension and Internal Medicine, Medical University of Lodz, 90-549 Lodz, Poland
3 shared publications - Aleksandra Kutaj
Poznan University of Medical Sciences, Poznan, Poland
2 shared publications - Beata Franczyk
Department of Nephrocardiology, Medical University of Lodz, 90-419 Lodz, Poland
2 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
"DISHphagia" - AN UNUSUAL CAUSE OF DYSPHAGIA IN A PATIENT WITH DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS: A CASE REPORT AND LITERATURE REVIEW
Background: Diffuse idiopathic skeletal hyperostosis (DISH) is a non-inflammatory, chronic, systemic disorder characterized by ossification of entheses, primarily affecting the spine. DISH is mostly asymptomatic but can manifest with chronic pain, limitation of spinal mobility, and rarely dysphagia. Aim: Our aim is to highlight the significance of DISH and its prevalence in the general population, as well as to raise awareness among clinicians of its role in the differential diagnosis of dysphagia, given that few similar cases have been reported and that surgical management is associated with a good prognosis. Description of the case: A 66-year-old male was admitted to the Department of Neurosurgery with a nine-year history of dysphagia and neck stiffness, which worsened over the preceding two years. CT and MRI scans revealed diffuse calcification of the anterior spinal ligament consistent with a diagnosis of DISH. The patient underwent surgical removal of osteophytes at the C4–C5–C6 levels. Postoperatively, the patient showed no neurological deficits, with only mild intermittent swallowing difficulties that considerably improved. Conclusions: DISH should be considered in the differential diagnosis of chronic dysphagia in elderly patients, particularly when associated with cervical pain or reduced neck mobility. Surgical removal of osteophytes may provide substantial symptomatic relief in selected patients with severe or progressive symptoms. Increased awareness of this uncommon presentation may facilitate earlier diagnosis and treatment.
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open Access"DISHphagia" - AN UNUSUAL CAUSE OF DYSPHAGIA IN A PATIENT WITH DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS: A CASE REPORT AND LITERATURE REVIEW
Background: Diffuse idiopathic skeletal hyperostosis (DISH) is a non-inflammatory, chronic, systemic disorder characterized by ossification of entheses, primarily affecting the spine. DISH is mostly asymptomatic but can manifest with chronic pain, limitation of spinal mobility, and rarely dysphagia. Aim: Our aim is to highlight the significance of DISH and its prevalence in the general population, as well as to raise awareness among clinicians of its role in the differential diagnosis of dysphagia, given that few similar cases have been reported and that surgical management is associated with a good prognosis. Description of the case: A 66-year-old male was admitted to the Department of Neurosurgery with a nine-year history of dysphagia and neck stiffness, which worsened over the preceding two years. CT and MRI scans revealed diffuse calcification of the anterior spinal ligament consistent with a diagnosis of DISH. The patient underwent surgical removal of osteophytes at the C4–C5–C6 levels. Postoperatively, the patient showed no neurological deficits, with only mild intermittent swallowing difficulties that considerably improved. Conclusions: DISH should be considered in the differential diagnosis of chronic dysphagia in elderly patients, particularly when associated with cervical pain or reduced neck mobility. Surgical removal of osteophytes may provide substantial symptomatic relief in selected patients with severe or progressive symptoms. Increased awareness of this uncommon presentation may facilitate earlier diagnosis and treatment.
- Open Access
- 6 March 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 52, 69364
Tirzepatide - a new drug with great potential in controlling glycemia and body weight
Introduction and Purpose: Type 2 diabetes mellitus (T2DM) and obesity are major global public health challenges associated with increased morbidity, mortality, and reduced quality of life. Despite multiple pharmacological therapies, achieving optimal glycemic control and sustained weight reduction remains difficult in many patients. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a promising therapeutic option. The aim of this review is to evaluate the clinical efficacy, safety profile, mechanism of action, and therapeutic potential of tirzepatide in the management of T2DM and obesity. Methods: A narrative review of current literature, including randomized controlled trials, meta-analyses, and European Medicines Agency documentation, was conducted to assess metabolic effects, dosing strategies, adverse events, and long-term implications of tirzepatide therapy. Results: Clinical trials show significant reductions in glycated hemoglobin (HbA1c), exceeding 2 percentage points in patients with T2DM, and dose-dependent body weight reduction of up to approximately 20% of baseline weight in individuals with obesity. Comparative analyses indicate greater efficacy than selective GLP-1 receptor agonists and basal insulin for glycemic control and weight reduction. The most common adverse events are gastrointestinal and occur mainly during dose escalation. Long-term cardiovascular and renal outcomes remain under investigation. Conclusions: Tirzepatide represents an important advancement in incretin-based therapy, offering combined metabolic benefits that may modify current treatment algorithms for T2DM and obesity. Although evidence supports high efficacy and acceptable safety, further long-term studies are needed to determine its effects on disease progression, cardiovascular outcomes, and sustained weight management.
- 6 March 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 52, 69364
Open AccessTirzepatide - a new drug with great potential in controlling glycemia and body weight
Introduction and Purpose: Type 2 diabetes mellitus (T2DM) and obesity are major global public health challenges associated with increased morbidity, mortality, and reduced quality of life. Despite multiple pharmacological therapies, achieving optimal glycemic control and sustained weight reduction remains difficult in many patients. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a promising therapeutic option. The aim of this review is to evaluate the clinical efficacy, safety profile, mechanism of action, and therapeutic potential of tirzepatide in the management of T2DM and obesity. Methods: A narrative review of current literature, including randomized controlled trials, meta-analyses, and European Medicines Agency documentation, was conducted to assess metabolic effects, dosing strategies, adverse events, and long-term implications of tirzepatide therapy. Results: Clinical trials show significant reductions in glycated hemoglobin (HbA1c), exceeding 2 percentage points in patients with T2DM, and dose-dependent body weight reduction of up to approximately 20% of baseline weight in individuals with obesity. Comparative analyses indicate greater efficacy than selective GLP-1 receptor agonists and basal insulin for glycemic control and weight reduction. The most common adverse events are gastrointestinal and occur mainly during dose escalation. Long-term cardiovascular and renal outcomes remain under investigation. Conclusions: Tirzepatide represents an important advancement in incretin-based therapy, offering combined metabolic benefits that may modify current treatment algorithms for T2DM and obesity. Although evidence supports high efficacy and acceptable safety, further long-term studies are needed to determine its effects on disease progression, cardiovascular outcomes, and sustained weight management.
- Open Access
- 16 November 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 85, 66605
A large retropharyngeal lipoma causing upper airway obstruction in a 64-year-old patient: case study
Introduction and Purpose Retropharyngeal lipomas are extremely rare benign mesenchymal tumors that often remain asymptomatic until reaching a considerable size. Due to their deep anatomical location, they may cause progressive airway or digestive tract compression, leading to potentially life-threatening symptoms. The purpose of this case report is to present a large retropharyngeal lipoma causing upper airway obstruction, outline the diagnostic difficulties, and describe the surgical management. Material and Methods A 64-year-old male patient with a one-month history of worsening dyspnea, dysphagia, and orthopnea was evaluated using computed tomography (CT) and magnetic resonance imaging (MRI). Imaging studies assessed the size, boundaries, and anatomical relationships of the lesion. The patient underwent planned tracheostomy followed by complete transpharyngeal surgical excision of the tumor. Histopathological examination was performed postoperatively. Results CT and MRI revealed a well-defined encapsulated fatty mass in the retropharyngeal space measuring up to 130 × 83 × 31 mm, leading to narrowing of the pharyngeal lumen and upper laryngeal segment. The lesion displaced adjacent cervical vascular structures and compressed the airway. Complete surgical removal was achieved without intraoperative complications. The postoperative course was uneventful, with successful decannulation on day 10. Histopathology confirmed a non-infiltrating lipoma with focal fibrolipomatous features. Conclusion Although benign, retropharyngeal lipomas may cause significant airway obstruction and require timely diagnosis and management. Precise radiological evaluation is essential to determine tumor extent and guide the surgical approach. Complete excision remains the treatment of choice, ensuring symptom resolution and minimizing the risk of recurrence or complications.
- 16 November 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 85, 66605
Open AccessA large retropharyngeal lipoma causing upper airway obstruction in a 64-year-old patient: case study
Introduction and Purpose Retropharyngeal lipomas are extremely rare benign mesenchymal tumors that often remain asymptomatic until reaching a considerable size. Due to their deep anatomical location, they may cause progressive airway or digestive tract compression, leading to potentially life-threatening symptoms. The purpose of this case report is to present a large retropharyngeal lipoma causing upper airway obstruction, outline the diagnostic difficulties, and describe the surgical management. Material and Methods A 64-year-old male patient with a one-month history of worsening dyspnea, dysphagia, and orthopnea was evaluated using computed tomography (CT) and magnetic resonance imaging (MRI). Imaging studies assessed the size, boundaries, and anatomical relationships of the lesion. The patient underwent planned tracheostomy followed by complete transpharyngeal surgical excision of the tumor. Histopathological examination was performed postoperatively. Results CT and MRI revealed a well-defined encapsulated fatty mass in the retropharyngeal space measuring up to 130 × 83 × 31 mm, leading to narrowing of the pharyngeal lumen and upper laryngeal segment. The lesion displaced adjacent cervical vascular structures and compressed the airway. Complete surgical removal was achieved without intraoperative complications. The postoperative course was uneventful, with successful decannulation on day 10. Histopathology confirmed a non-infiltrating lipoma with focal fibrolipomatous features. Conclusion Although benign, retropharyngeal lipomas may cause significant airway obstruction and require timely diagnosis and management. Precise radiological evaluation is essential to determine tumor extent and guide the surgical approach. Complete excision remains the treatment of choice, ensuring symptom resolution and minimizing the risk of recurrence or complications.
- Open Access
- 11 October 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (10) , 1439
Baxdrostat: A Next-Generation Aldosterone Synthase Inhibitor Offering New Hope in Resistant Hypertension
Hypertension is a leading global cause of cardiovascular disease and mortality, with resistant hypertension (RH) posing treatment challenges. Aldosterone synthase inhibitors (ASIs) are a novel drug class that reduce blood pressure by lowering aldosterone levels. Baxdrostat is a selective ASI that inhibits the CYP11B2 enzyme, responsible for aldosterone synthesis, without affecting cortisol production. This selectivity minimizes hormonal side effects. Clinical trials have shown that baxdrostat reduces plasma aldosterone in a dose-dependent manner while preserving cortisol levels. In the Phase 2 BrigHTN trial, baxdrostat significantly lowered systolic and diastolic blood pressure in patients with RH, with the 2 mg dose showing the most consistent efficacy. However, in the HALO trial, similar blood pressure reductions were observed in the placebo group, possibly due to improved adherence to background antihypertensive therapy. Baxdrostat has demonstrated a favorable safety profile, with mostly mild adverse effects and no significant impact on kidney function. It is considered safe for use with other medications, including metformin. Ongoing trials are investigating its potential in patients with chronic kidney disease (CKD) and primary hyperaldosteronism (PA). Baxdrostat represents a promising therapeutic option for aldosterone-driven hypertension, especially in patients unresponsive to standard treatments.
- 11 October 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (10) , 1439
Open AccessBaxdrostat: A Next-Generation Aldosterone Synthase Inhibitor Offering New Hope in Resistant Hypertension
Hypertension is a leading global cause of cardiovascular disease and mortality, with resistant hypertension (RH) posing treatment challenges. Aldosterone synthase inhibitors (ASIs) are a novel drug class that reduce blood pressure by lowering aldosterone levels. Baxdrostat is a selective ASI that inhibits the CYP11B2 enzyme, responsible for aldosterone synthesis, without affecting cortisol production. This selectivity minimizes hormonal side effects. Clinical trials have shown that baxdrostat reduces plasma aldosterone in a dose-dependent manner while preserving cortisol levels. In the Phase 2 BrigHTN trial, baxdrostat significantly lowered systolic and diastolic blood pressure in patients with RH, with the 2 mg dose showing the most consistent efficacy. However, in the HALO trial, similar blood pressure reductions were observed in the placebo group, possibly due to improved adherence to background antihypertensive therapy. Baxdrostat has demonstrated a favorable safety profile, with mostly mild adverse effects and no significant impact on kidney function. It is considered safe for use with other medications, including metformin. Ongoing trials are investigating its potential in patients with chronic kidney disease (CKD) and primary hyperaldosteronism (PA). Baxdrostat represents a promising therapeutic option for aldosterone-driven hypertension, especially in patients unresponsive to standard treatments.
- Top Cited PapersOpen Access
- 27 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1094
Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications
Type 2 diabetes mellitus (T2DM), a prevalent chronic disease affecting over 400 million people globally, is driven by genetic and environmental factors. The pathogenesis involves insulin resistance and β-cell dysfunction, mediated by mechanisms such as the dedifferentiation of β-cells, mitochondrial dysfunction, and oxidative stress. Treatment should be based on non-pharmacological therapy. Strategies such as increased physical activity, dietary modifications, cognitive-behavioral therapy are important in maintaining normal glycemia. Advanced therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, complement these treatments and offer solid glycemic control, weight control, and reduced cardiovascular risk. Complications of T2DM, such as diabetic kidney disease, retinopathy, and neuropathy, underscore the need for early diagnosis and comprehensive management to improve patient outcomes and quality of life.
- 27 January 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1094
Top Cited PapersOpen AccessType 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications
Type 2 diabetes mellitus (T2DM), a prevalent chronic disease affecting over 400 million people globally, is driven by genetic and environmental factors. The pathogenesis involves insulin resistance and β-cell dysfunction, mediated by mechanisms such as the dedifferentiation of β-cells, mitochondrial dysfunction, and oxidative stress. Treatment should be based on non-pharmacological therapy. Strategies such as increased physical activity, dietary modifications, cognitive-behavioral therapy are important in maintaining normal glycemia. Advanced therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, complement these treatments and offer solid glycemic control, weight control, and reduced cardiovascular risk. Complications of T2DM, such as diabetic kidney disease, retinopathy, and neuropathy, underscore the need for early diagnosis and comprehensive management to improve patient outcomes and quality of life.
- Top Cited PapersOpen Access
- 23 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10222
Novel Insights into Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a major complication of diabetes mellitus (DM), affecting over one-third of type 1 and nearly half of type 2 diabetes patients. As the leading cause of end-stage renal disease (ESRD) globally, DKD develops through a complex interplay of chronic hyperglycemia, oxidative stress, and inflammation. Early detection is crucial, with diagnosis based on persistent albuminuria and reduced estimated glomerular filtration rate (eGFR). Treatment strategies emphasize comprehensive management, including glycemic control, blood pressure regulation, and the use of nephroprotective agents such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Ongoing research explores novel therapies targeting molecular pathways and non-coding RNAs. Preventive measures focus on rigorous control of hyperglycemia and hypertension, aiming to mitigate disease progression. Despite therapeutic advances, DKD remains a leading cause of ESRD, highlighting the need for continued research to identify new biomarkers and innovative treatments.
- 23 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10222
Top Cited PapersOpen AccessNovel Insights into Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a major complication of diabetes mellitus (DM), affecting over one-third of type 1 and nearly half of type 2 diabetes patients. As the leading cause of end-stage renal disease (ESRD) globally, DKD develops through a complex interplay of chronic hyperglycemia, oxidative stress, and inflammation. Early detection is crucial, with diagnosis based on persistent albuminuria and reduced estimated glomerular filtration rate (eGFR). Treatment strategies emphasize comprehensive management, including glycemic control, blood pressure regulation, and the use of nephroprotective agents such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Ongoing research explores novel therapies targeting molecular pathways and non-coding RNAs. Preventive measures focus on rigorous control of hyperglycemia and hypertension, aiming to mitigate disease progression. Despite therapeutic advances, DKD remains a leading cause of ESRD, highlighting the need for continued research to identify new biomarkers and innovative treatments.